Study Title
1367.1: An open label, Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit
Protocol ID
1367.1
Disease (Sub Disease)
Kidney (Renal) Tumours
Diagnosis Stage
New Diagnosis
Relapse/Refractory
Relapse/Refractory
Sponsor
Boehringer Ingelheim
Links
Trial Status
Completed
Trial Close Date
23/11/2021
Study Type
Treatment
Phase
Phase 1
Age Eligibility
18 Years and older
International registry ID's
NCT02516553
| Study Title | 1367.1: An open label Phase Ia/Ib dose finding study with BI 894999 orally administered once a day in patients with advanced malignancies with repeated administration in patients with clinical benefit |
|---|---|
| Protocol ID | 1367.1 |
| Disease (Sub Disease) | Kidney (Renal) Tumours |
| Diagnosis Stage | New Diagnosis Relapse/Refractory |
| Sponsor | Boehringer Ingelheim |
| Links | https://clinicaltrials.gov/ct2/show/NCT02516553 |
| Trial Status | Completed |
| Trial Open Date | 09/12/2020 |
| Trial Close Date | 23/11/2021 |
| Study Type | Treatment |
| Phase | Phase 1 |
| Age Eligibility | 18 Years and older |
| International registry ID's | NCT02516553 |